Microarray analysis reveals distinct gene expression profiles among different tumor histology, stage and disease outcomes in endometrial adenocarcinoma

PLoS ONE

Volumn 5, Issue 11, 2010, Pages

  Mhawech Fauceglia, Paulette ^a   Wang, Dan ^a   Kesterson, Joshua ^a   Clark, Kimberly ^a   Monhollen, Laketa ^a   Odunsi, Kunle ^a   Lele, Shashikant ^a   Liu, Song ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CCAAT ENHANCER BINDING PROTEIN; CHICKEN OVALBUMIN UPSTREAM PROMOTER TRANSCRIPTION FACTOR 1; CONTACTIN; CONTACTIN 1; E74 LIKE FACTOR 5 PROTEIN; EPHRIN RECEPTOR A1; FIBULIN; FIBULIN 1; HOX PROTEIN; KINESIN; KINESIN FAMILY MEMBER 14 PROTEIN; LYSOPHOSPHATIDIC ACID RECEPTOR; LYSOPHOSPHATIDIC ACID RECEPTOR 2; NONMETASTATIC CELL 3 PROTEIN; PROTEIN APLNR; PROTEIN FST; PROTEIN HOXD10; PROTEIN LMO4; PROTEIN RPRM; RAS ASSOCIATION DOMAIN FAMILY 7 PROTEIN; RHO GUANINE NUCLEOTIDE BINDING PROTEIN; RHO RELATED BTB DOMAIN CONTAINING PROTEIN 3; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR FOSB; TREFOIL FACTOR 3 PROTEIN; TREFOIL PEPTIDE; TUMOR PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CANCER STAGING; CONTROLLED STUDY; EARLY CANCER; ENDOMETRIUM CARCINOMA; FEMALE; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MICROARRAY ANALYSIS; OUTCOME ASSESSMENT; PROGNOSIS; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; TUMOR GROWTH; TUMOR VOLUME; UTERUS CARCINOMA; CLUSTER ANALYSIS; CYSTADENOCARCINOMA; DNA MICROARRAY; ENDOMETRIOID CARCINOMA; ENDOMETRIUM TUMOR; GENE EXPRESSION REGULATION; GENETICS; METHODOLOGY; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UTERUS CANCER;

CARCINOMA, ENDOMETRIOID; CLUSTER ANALYSIS; CYSTADENOCARCINOMA, SEROUS; ENDOMETRIAL NEOPLASMS; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOPLASM STAGING; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; UTERINE NEOPLASMS;

EID: 78149472081     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0015415.s001     Document Type: Article

References (51)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, et al. (2009) Cancer Satistics; CA cancer J Clin 59: 225-249.
2. Soslow RA, Bissonnette JP, Wilton A, Ferguson SE, Alektiar KM, et al. (2007) Clinicopathologic analysis of 187 high-grade endometrial carcinomas of different histologic subtypes: Similar outcomes belie distinctive biologic differences. Am J Surg Pathol 31: 979-87.
3. Kitchener HC, Trimble EL; Endometrial Cancer Working Group of the Gynecoloic Cancer Intergroup (2009) Endometrial cancer state of the science meeting. Int J Gynecol Cancer 9: 134-140.
4. Sutton G, Axelrod JH, Bundy BN, Bundy BN, Roy T, et al. (2005) Whole abdominal radiotherapy in the adjuvant treatment of patients with stage III and IV endometrial cancer: a gynecologic oncology group study. Gynecol Oncol 97: 755-63.
5. Naumann RW (2008) Uterine papillary serous carcinoma state of the state. Current Oncology reports 10: 505-511.
6. Benito V, Lubrano A, Arencibia O, Alvarez EE, León L, et al. (2009) Pure papillary serous tumors of the endometrium. A clinicopathological analysis of 61 cases from a single institution. Int J Gynecol Cancer 19: 1364-1369.
7. Tashiro H, Blazes MS, Wu R, Cho KR, Bose S, et al. (1997) Mutations in PTEN are frequent in endometrial carcinoma but rare in other common gynecological malignancies. Cancer Res 57: 3935-3940.
8. Risinger JI, Berchuck A, Kohler MF, Watson P, Lynch HT, et al. (1993) Genetic instability of microsatellites in endometrial carcinoma. Cancer Res 58: 5100-5103.
9. Lukes AS, Kohler MF, Pieper CF, Kerns BJ, Bentley R, et al. (1994) A multivariable analysis of DNA ploidy, p53, and Her-2/neu as prognostic factors in endometrial cancer. Cancer 73: 2380-2385.
10. Kohler MF, Berchuck A, Davidoff AM, Humphrey PA, Dodge RK, et al. (1992) Overexpression and mutation of p53 in endometrial carcinoma. Cancer Res 52: 1622-1627.
11. Santin AD, Zhan F, Cane' S, Bellone S, Palmieri M, et al. (2005) Gene expression fingerprint of uterine serous papillary carcinoma: identification of novel molecular markers for uterine serous cancer diagnosis and therapy. Br J Cancer 92: 1561-1573.
12. Palanaguma J, Diaz-fuertes M, Gil-Moreno A, Abal M, Monge M, et al. (2004) A differential gene expression profile reveals overexpression of RUNX1/AML1 in invasive endometrioid carcinoma. Cancer Res 64: 8846-8853.
13. Smid-Koopman E, Blok LJ, Helmerhorst TJ, Chadha-Ajwani S, Burger CW, et al. (2004) Gene expression profiling in human endometrial cancer tissue samples: utility and diagnostic value. Gynecol Oncol 93: 292-300.
14. Moreno-Bueno G, Sanchez-Estevez C, Cassia R, Rodríguez-Perales S, Daz-Uriarte R, et al. (2003) Differential gene expression profile in endometrioid and nonendometrioid endometrial carcinoma; STK15 is frequently overexpressed and amplified in nonendometrioid carcinomas. Cancer Res 63: 5697-5702.
15. Zorn KK, Bonome T, Gangi L, Chandramouli GV, Awtrey CS, et al. (2005) Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial cancer. Clin Cancer Res 11: 6422-6430.
16. Risinger JI, Maxwell GL, Chandramouli GV, Jazaeri A, Aprelikova O, et al. (2003) Microarray analysis reveals distinct gene expression profiles among different histologic types of endometrial cancer. Cancer Res 63: 6-11.
17. Maxwell GL, Chandramouli GVR, Dainty L, Litzi TJ, Berchuck A, et al. (2005) Microarray analysis of endometrial carcinomas and mixed mullerian tumors reveals distinct gene expression profiles associated with different histologic types of uterine cancer. Clin Cancer Res 11: 4056-4066.
18. Campbell TN, Robbins SM. The Eph receptor/ephrin system: an emerging player in the invasion game. Curr Isssues Mol Biol 2008 10: 61-66.
19. Herath NI, Doecke J, Spanevello MD, Leggett BA, Boyd AW (2009) Epigenetic silencing of EphA1 expression in colorectal cancer is correlated with poor survival. Br J Cancer 100: 1095-1102.
20. Herath NI, Spanevello MD, Sabesan S, Newton T, Cummings M, et al. (2006) Over-expression of Eph and ephrin genes in advanced ovarian cancer: ephrin gene expression correlates with shortened survival. BMC Cancer 6: 144-151.
21. Babyatsky M, Lin J, Yio X, Chen A, Zhang JY, et al. (2009) Trefoil factor-3 expression in human colon liver metastasis. Clin Exp Metastasis 26: 143-151.
22. Bignotti E, Ravaggi A, Tassi RA, Calza S, Rossi E, et al. (2008) Trefoil factor 3: a novel serum marker identified by gene expression profiling in high-grade endometrial carcinomas. Br J Cancer 99: 768-773.
23. Zhou j, Ng AY, Tymms MJ, Jermiin LS, Seth AK, et al. (1998) A novel transcription factor, ELF5, belongs to the ELF subfamily of ETS genes and maps to human chromosome 11p13-15, a region subject to LOH and rearrangement in human carcinoma cell lines. Oncogene 17: 2719-2732.
24. Mills GB, Moolenaar WH (2003) The emerging role of lysophosphatidic acid in cancer. Nat Rev 3: 582-591.
25. Yu S, Murph MM, Lu Y, Liu S, Hall HS, et al. (2008) Lysophosphatidic acid receptors determine tumorigenicity and aggressiveness of ovarian cancer cells. J Natl Cancer Inst 100: 1630-1642.
26. Maitra A, Hansel DE, Argani P, Ashfaq R, Rahman A, et al. (2003) Global expression analysis of well-differentiated pancreatic endocrine neoplasms using oligonulceotide microarrays. Clin Cancer Res 9: 5988-5995.
27. Kieback DG, Levi T, Kohlberger P Fiedrich U, Press MF, et al. (1996) Chicken ovalbumin upstream promoter-transcription factor (COUP-TF) expression in human endometrial cancer cell lines. Anticancer Res 16: 3371-3376.
28. Schäfer G, Wissmann C, Hertel J, Lunyak V, Höcker M (2008) Regulation of vascular endotehlail growth factor D by orphan recpetors hepatocyte nuclear factor-4á and chicken ovalbumin upstream promoter transcription factors 1 and 2. Cancer Res 68: 457-466.
29. Su JL, Yang CY, Shih JY, Wei LH, Hsieh CY, et al. (2006) Knockdown of contactin-1 expression supresses invasion and metastasis of lung adencoarcinoma. Cancer Res 66: 2553-2561.
30. Kim T-M, Yim S-H, Shin S-H, Xu HD, Jung YC, et al. (2008) Clinical implication of recurrent copy number alterations in hepatocellular carcinoma and a putative oncogenes in recurrent gains on 1q. Int J Cancer 123: 2808-2815.
31. Corson TW, Huang A, Tsao M-S, Gallie BL (2005) KIF14 is a candidate oncogene in the 1q minimal region of genomic gain in multiple cancers. Oncogene 24: 4741-4753.
32. Markowski J, Oczko-Wojciechowska M, Gierek T, Jarzab M, Paluch J, et al. (2009) Gene expression profile analysis in laryngeal cancer by high-density oligonucleotide microarrays. J Physiol Pharmacol 60 (suppl 1): 57-63.
33. Corson TW, Gallie BL (2006) KIF14 mRNA expression is a predictor of grade and outcome in breast cancer. Int J Cancer 119: 1088-1094.
34. Taylor HS (2000) The role of HOX genes in the development and function of the female reproductive tract. Semin Reprod Med 18: 81-89.
35. Osborne J, Hu C, Hawley C, Underwood LJ, O'Brien TJ, et al. (1998) Expression of HOXD10 gene in normal endometrium and endometrial adenocarcinoma. J Soc Gynecol Investig 5: 277-280.
36. Gómez del Pulgar T, Benitah SA, Valerón PF, Espina C, Lacal JC (2005) Rho GTPase expression in tumourigenesis: evidence for a significant link. Bioessays 27: 602-613.
37. Aznar S, Fernández-Valerón P, Espina C, Lacal CJ (2004) Rho GTPases: potential candidates for anticancer therapy. Cancer Letters 206: 181-191.
38. Berthold J, Schenkova K, Rivero F (2008) RhoGTPases of the RhoBTB subfamily and tumorigenesis. Acta Pharmacol Sin 29: 285-295.
39. Van der Weyden L, Adams DJ (2007) The Ras-association domain family (RASSF) members and their role in human tumourigenesis. Biochimica et Biophysica Acta 1776: 58-85.
40. Sherwood V, Manbodh R, Sheppard C, Chalmers AD (2008) RASSF1is a member of a new family of RAS association domain-containing proteins and is required completing mitosis. Mol Biol Cell 19: 1772-1782.
41. Richter AM, Pfeifer GP, Dammann RH (2009) The RASSF proteins in cancer; from epigenetic silencing to functional characterization. Biochimica et Biophysica Acta 1796: 114-128.
42. Wlazlinski A, Engers R, Hoffmann MJ, Hader C, Jung V, et al. (2007) Downregulation of several fibulin genes in prostate cancer. Prostate 67: 1770-1780.
43. Cheng YY, Jin H, Liu X, Siu JM, Wong YP, et al. Fibulin 1 is downregulated through promoter hypermethylation in gastric cancer. Br J Cancer 99: 2083-2087.
44. Gallagher WM, Currid CA, Whelan LC (2005) Fibulins and cancer: friend or foe? Trends in Molecular Medicine 11: 336-340.
45. NCCN Clinical Practice Guidelines in Oncology. Uterine Neoplasms V.1.2010. www.nccn.org.
46. Idaghdour Y, Storey JD, Jadallah SJ, Gibson G (2008) A genome-wide gene expression signature of environmental geography in leukocytes of Moroccan Amazighs. PLoS Genet 4: e1000052.
47. Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, et al. (2004) Bioconductor: open software development for computational biology and bioinformatics. Genome Biol 5: R80.
48. Du P, Kibbe WA, Lin SM (2008) Lumina pipeline for processing Illumina microarray. Bioinformatics 24: 1547-8.
49. Smyth GK (2004) Linear models and empirical Bayes methods for assessing differential expression in microarray experiments. Statistical Applications in Genetics and Molecular Biology 3: R3.
50. Eisen MB, Spellman PT, Brown PO, Botstein D (1998) Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci USA 95: 14863-8.
51. Huang W, Sherman BT, Tan Q, Kir J, Liu D, et al. (2007) DAVID Bioinformatics Resources: expanded annotation database and novel algorithms to better extract biology from large gene lists. Nucleic Acids Res 35: W169-75.